Evidence Grade B — Strong clinical evidence. 410 published studies, 248 human. 36 registered clinical trials.
Medically reviewed by a licensed medical professional
Carbetocin is a long-acting version of oxytocin that has been studied to prevent dangerous bleeding after childbirth. It is registered in over 80 countries outside the US but has never received FDA approval. A heat-stable formulation — one that does not need refrigeration — was added to the WHO Essential Medicines List, addressing a critical need in tropical and low-resource settings where standard oxytocin degrades in the heat.
Carbetocin is also known by these brand and alternate names:
410 published studies: 248 human, 73 animal, 17 in-vitro, 75 reviews
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019.
The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Carbetocin activates the same oxytocin receptor as natural oxytocin, producing uterine contractions. Its molecular structure includes a modification that prevents the body from breaking it down as quickly as natural oxytocin, extending its duration of action to approximately 40 minutes compared to oxytocin's 3–17 minutes. This longer action means a single dose may be sufficient where oxytocin would require a continuous infusion.
The WHO-sponsored CHAMPION trial (over 29,000 women) found heat-stable carbetocin non-inferior to oxytocin for preventing postpartum haemorrhage after vaginal delivery. This matters because standard oxytocin requires refrigeration, which is often unreliable in the regions where postpartum haemorrhage is the leading cause of maternal death. The US market has not been pursued, likely because reliable cold-chain oxytocin is ubiquitous in US healthcare facilities. A development programme for Prader-Willi syndrome (a genetic condition) failed, closing the most advanced pathway for major-market development. Carbetocin's global health significance rests on the heat-stable formulation for resource-limited settings.
PeptideTrace tracks 36 registered clinical trials for Carbetocin sourced from ClinicalTrials.gov.
Effect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery
Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section
Timing of Carbetocin Administration in Postpartum Hemorrhage
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Health Canada Market Authorisation
Carbetocin (1-deamino-1-monocarba oxytocin) is a long-acting synthetic oxytocin analogue in which the disulfide bridge is replaced with a thioether linkage, preventing enzymatic reduction and extending the half-life to approximately 40 minutes (versus 3–5 minutes for oxytocin). It has never been approved by the FDA.
Carbetocin activates the oxytocin receptor (OXTR) via the same Gq/PLC/IP3 signaling pathway as oxytocin, producing uterine smooth muscle contraction. The thioether modification provides extended receptor occupancy and a longer duration of uterotonic action compared to oxytocin, enabling single-dose administration for PPH prevention rather than the continuous infusion required with oxytocin.
Carbetocin has never been FDA-approved in the United States. It is registered in over 80 countries for prevention of postpartum hemorrhage following cesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019, addressing the cold-chain limitation of oxytocin in low-resource settings. The WHO CHAMPION trial (~30,000 women across 10 countries) demonstrated carbetocin was non-inferior to oxytocin for PPH prevention. Acadia Pharmaceuticals pursued intranasal carbetocin for Prader-Willi syndrome (hyperphagia), but the Phase 3 COMPASS PWS trial failed its primary endpoint in September 2025, and Acadia announced discontinuation of the program.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Kisspeptin-54 has no marketing authorisation. Phase II trials conducted primarily at Imperial College London have investigated its use as an IVF oocyte maturation trigger. One trial (60 patients) reported 95% oocyte maturation with zero cases of ovarian hyperstimulation syndrome. Kisspeptin-54 has a more advanced clinical evidence base than kisspeptin-10, with multiple Phase II studies in reproductive medicine. Its potential advantage over conventional IVF triggers relates to a lower risk of the serious complication of ovarian hyperstimulation. Clinical development is ongoing in academic settings. No Phase III trials have been completed.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Leuprolide is marketed as Lupron Depot, Eligard, and Fensolvi, and was first approved in 1985. It is available in depot formulations lasting one, three, four, or six months. Its clinical applications span multiple specialities: oncology (advanced prostate cancer), gynaecology (endometriosis, uterine fibroids), paediatric endocrinology (central precocious puberty), and reproductive medicine. Leuprolide's long clinical history provides extensive safety data. The initial hormone surge in the first one to two weeks can temporarily worsen symptoms — a well-known effect called 'flare' that is managed by co-prescribing an anti-androgen in prostate cancer patients. Long-term use carries risks including bone density loss, cardiovascular effects, and metabolic changes. Despite the availability of newer GnRH antagonists that avoid the initial flare, leuprolide remains the dominant treatment in this category due to its proven track record and range of formulations.
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
